What is Granulomatosis with polyangiitis?
Granulomatosis with polyangiitis (GPA), formerly known as Wegener granulomatosis, is a rare autoimmune disease that causes inflammation of blood vessels throughout the body. This ANCA-associated vasculitis primarily affects small to medium-sized blood vessels in the respiratory tract, kidneys, and other organs. GPA affects approximately 3 in every 100,000 people worldwide, with peak onset typically occurring between ages 40-60. While rare and serious, early diagnosis and modern treatments have significantly improved outcomes for people living with this condition.
Key statistics
| Prevalence: | ~3 per 100,000 people |
| Annual incidence: | 0.5-1 per 100,000 people |
| Peak age of onset: | 40-60 years |
| 5-year survival with treatment: | >90% |
Symptoms
Common symptoms: chronic sinusitis, bloody nasal discharge, saddle-nose deformity, cough, shortness of breath, fatigue, weight loss, joint pain, skin rashes, eye inflammation, kidney problems.
Early symptoms often mimic common respiratory infections, making diagnosis challenging. The upper respiratory tract is frequently affected first, with persistent sinusitis, nosebleeds, and nasal crusting. Patients may develop a characteristic saddle-nose deformity due to cartilage destruction. Pulmonary involvement presents as persistent cough, shortness of breath, chest pain, and sometimes coughing up blood. Lung imaging typically reveals nodules or infiltrates.
Kidney involvement, called glomerulonephritis, may initially be silent but can progress to kidney failure. Early signs include blood in urine, protein in urine, and elevated blood pressure. Constitutional symptoms like fatigue, fever, weight loss, and muscle aches are common. Eye involvement can cause redness, pain, and vision changes. Skin manifestations include purpura, ulcers, and nodules. Joint pain and swelling, particularly in large joints, affects many patients.
Causes and risk factors
GPA is an autoimmune disease where the immune system mistakenly attacks healthy blood vessels, causing inflammation and tissue damage. The exact trigger remains unknown, but it’s classified as an ANCA-associated vasculitis, characterized by specific antibodies called anti-neutrophil cytoplasmic antibodies.
The disease is not inherited in a traditional genetic pattern, though certain genetic factors may increase susceptibility. Environmental triggers may include infections, particularly Staphylococcus aureus nasal carriage, exposure to silica dust, and certain medications. Risk factors include being of Northern European descent, middle age, and possibly seasonal allergies or chronic sinusitis. Unlike purely genetic conditions, GPA appears to result from complex interactions between genetic predisposition and environmental factors.
Prevention
Currently, there are no proven methods to prevent GPA since the exact triggers remain unclear. Unlike inherited genetic conditions, GPA is not passed from parents to children, so genetic testing and carrier screening are not applicable. However, some strategies may help reduce infection-related flares in diagnosed patients, such as treating nasal Staphylococcus aureus colonization and maintaining good respiratory hygiene. Early recognition of symptoms and prompt medical evaluation represent the most effective approaches to preventing serious complications. Family members do not require special screening, but awareness of symptoms may facilitate earlier diagnosis if the condition develops.
Complications
Without treatment, GPA can cause life-threatening organ damage. Kidney failure is a major concern, potentially requiring dialysis or transplantation. Pulmonary complications include lung scarring, bleeding, and respiratory failure. Destruction of nasal cartilage can cause permanent facial deformity and hearing loss. Eye complications may lead to vision loss or blindness.
Chronic inflammation can damage the nervous system, causing peripheral neuropathy or stroke. Heart involvement, while less common, can result in pericarditis or myocarditis. Untreated GPA historically had a mortality rate exceeding 90% within two years. Even with treatment, patients face increased risks of infections due to immunosuppressive medications, cardiovascular disease, and secondary cancers. Long-term complications may include chronic kidney disease, persistent respiratory symptoms, and treatment-related side effects.
Diagnosis
Diagnosing GPA requires combining clinical symptoms, laboratory tests, imaging, and often tissue biopsy. The diagnostic journey can be lengthy and challenging, as early symptoms often mimic more common conditions.
Blood tests include c-ANCA (cytoplasmic anti-neutrophil cytoplasmic antibodies) and specifically anti-PR3 antibodies, which are positive in approximately 80-90% of patients with generalized disease. Complete blood count may show anemia or elevated white blood cells. Kidney function tests (creatinine, blood urea nitrogen) and urinalysis detect kidney involvement. Inflammatory markers like erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are typically elevated.
Imaging studies include chest X-rays and CT scans showing pulmonary nodules, infiltrates, or cavities. Sinus CT scans reveal chronic sinusitis and bone destruction. Tissue biopsy from affected organs (nasal tissue, lung, kidney) shows characteristic necrotizing granulomatous inflammation and vasculitis, providing definitive diagnosis. The 2012 Chapel Hill Consensus Conference criteria help standardize diagnosis.
Treatment
Modern treatment has revolutionized GPA outcomes, typically involving induction therapy to achieve remission followed by maintenance therapy to prevent relapses.
Induction therapy for severe disease includes cyclophosphamide combined with high-dose corticosteroids, or rituximab as an alternative first-line option. For limited disease, methotrexate with corticosteroids may suffice. Avacopan, a complement C5a receptor antagonist, represents a newer treatment option that may reduce steroid requirements.
Maintenance therapy typically involves less toxic immunosuppressants like methotrexate, azathioprine, or mycophenolate mofetil. Some patients benefit from low-dose rituximab for maintenance. Corticosteroids are gradually tapered as other medications take effect.
Supportive care includes treating infections, managing hypertension, bone protection during steroid use, and Pneumocystis prophylaxis during intensive immunosuppression. Plasma exchange may be used for severe kidney disease or pulmonary hemorrhage. Close monitoring for treatment response and side effects is essential.
Prognosis
With modern treatment, the prognosis for GPA has improved dramatically. Five-year survival rates exceed 90%, compared to historical mortality rates of over 90% within two years without treatment. However, the disease requires lifelong management, and many patients experience relapses requiring treatment adjustments.
Factors affecting prognosis include extent of organ involvement at diagnosis, response to initial treatment, and ability to achieve sustained remission. Kidney involvement and advanced age at diagnosis may indicate more challenging disease courses. Most patients can achieve remission, though complete cure remains elusive. Quality remission – maintaining normal organ function with minimal medication side effects – is an achievable goal for many patients. Long-term outlook depends on preventing relapses while minimizing treatment toxicity.
Quality of life
Living with GPA requires adapting to a chronic condition while maintaining an active, fulfilling life. Many patients successfully return to work, travel, and pursue hobbies during remission periods. Regular exercise, when approved by healthcare providers, helps maintain strength and cardiovascular health while potentially reducing inflammation.
Dietary considerations include adequate calcium and vitamin D during steroid treatment, limiting salt if hypertensive, and maintaining good nutrition during active disease. Sleep quality may be affected by medications or disease symptoms, requiring good sleep hygiene practices. Mental health support is crucial, as chronic illness and immunosuppressive treatments can contribute to anxiety and depression.
Patients should avoid live vaccines due to immunosuppression and take precautions against infections. Stress management through relaxation techniques, support groups, or counseling can help manage the psychological impact of chronic illness. Many patients find maintaining social connections and pursuing meaningful activities essential for emotional well-being.
Pregnancy and fertility
GPA and its treatments can affect fertility and pregnancy outcomes, requiring specialized care from maternal-fetal medicine specialists and rheumatologists. Some immunosuppressive medications, particularly cyclophosphamide, can impair fertility in both men and women. Fertility preservation options should be discussed before starting treatment in patients of reproductive age.
During pregnancy, certain medications require modification or discontinuation. Methotrexate and cyclophosphamide are contraindicated, while azathioprine and certain corticosteroids are generally considered safer options. Rituximab use requires careful consideration. Disease activity should be optimally controlled before conception when possible.
Pregnant women with GPA require increased monitoring for disease flares and pregnancy complications. Some patients experience disease improvement during pregnancy, while others may have increased activity. Genetic counseling is generally not necessary since GPA is not inherited, though discussion of family planning in the context of chronic disease management is valuable.
Children
Pediatric GPA is extremely rare, accounting for less than 5% of all cases. Children typically present with upper respiratory symptoms, making diagnosis even more challenging than in adults. The disease course in children may be more aggressive, with higher rates of subglottic stenosis and growth concerns related to chronic corticosteroid use.
Treatment approaches are similar to adults but require careful attention to growth and development. Medication dosing is adjusted for body weight, and long-term steroid effects on growth, bone development, and immune system maturation require monitoring. Educational accommodations may be necessary during active disease periods or treatment intensification.
Family support and age-appropriate education about the condition help children cope with chronic illness. Transition planning to adult care providers typically begins during adolescence, ensuring continuity of specialized care.
When to see a doctor
Immediate medical attention is required for: coughing up blood, severe breathing difficulties, sudden vision changes, signs of kidney problems (blood in urine, swelling, decreased urination), severe headaches with neurological symptoms, or signs of serious infection during immunosuppressive treatment.
Routine medical care should be sought for: persistent sinus symptoms lasting more than several weeks, chronic cough or respiratory symptoms, unexplained fatigue and weight loss, joint pain and swelling, or skin rashes and ulcers. Given the rarity and complexity of GPA, referral to rheumatology or specialized vasculitis centers is typically necessary for diagnosis and management.
Patients with established GPA should maintain regular follow-up appointments and report any concerning symptoms promptly, as early intervention during relapses improves outcomes.
Regional context
Limited specific data exists regarding GPA prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries. The condition appears to be less common in populations of Middle Eastern and Asian descent compared to Northern European populations, though cases certainly occur across all ethnic groups.
Environmental factors specific to these regions, such as endemic infections or occupational exposures, may influence disease presentation or triggers. We invite healthcare providers and researchers from these regions to contribute their clinical experiences and epidemiological data to improve understanding of GPA in diverse populations through the Global Medical Journal.
Research and clinical trials
Current research focuses on developing more targeted therapies with fewer side effects, understanding disease triggers, and identifying biomarkers to predict relapses. Studies are investigating novel biologics, including other B-cell depleting agents and complement inhibitors beyond avacopan.
Researchers are exploring the role of infections in triggering disease and relapses, potentially leading to preventive strategies. Genetic studies aim to identify susceptibility factors that might guide personalized treatment approaches. Clinical trials are evaluating maintenance therapy strategies to reduce relapse rates while minimizing long-term treatment toxicity.
Patients can find current clinical trials through ClinicalTrials.gov, and major vasculitis centers often participate in research studies. The Vasculitis Clinical Research Consortium coordinates multi-center studies advancing understanding and treatment of ANCA-associated vasculitis.
Frequently asked questions
Is GPA contagious?
No, GPA is not contagious. It’s an autoimmune disease where your immune system attacks your own blood vessels. You cannot catch it from or transmit it to others.
Will I need treatment for life?
Most patients require long-term treatment to maintain remission and prevent relapses. However, treatment intensity often decreases over time, and some patients may eventually discontinue medications while remaining in remission.
Can I live a normal life with GPA?
Yes, many people with GPA live full, active lives during remission. While the condition requires ongoing medical care and monitoring, most patients can work, travel, exercise, and maintain relationships normally.
What triggers GPA flares?
Common triggers include infections, stress, and sometimes medication changes. However, flares can occur without identifiable triggers. Maintaining good overall health and following treatment plans helps reduce flare risk.
How often will I need medical monitoring?
Monitoring frequency depends on disease activity and treatment phase. During active treatment, monthly visits may be necessary. During stable remission, visits every 3-6 months are typical, with regular blood tests to monitor for relapses and treatment side effects.
Support and resources
Vasculitis Foundation – Primary patient organization providing education, support, and advocacy: https://www.vasculitisfoundation.org
Orphanet – Comprehensive rare disease database: https://www.orpha.net
National Organization for Rare Disorders (NORD): https://rarediseases.org
EURORDIS-Rare Diseases Europe: https://www.eurordis.org
American College of Rheumatology – Professional guidelines and patient resources: https://www.rheumatology.org
ClinicalTrials.gov – Clinical trial database: https://clinicaltrials.gov
These organizations provide educational materials, connect patients with others facing similar challenges, and advocate for research and improved treatments.
Related conditions
Microscopic polyangiitis
Eosinophilic granulomatosis with polyangiitis
Polyarteritis nodosa
Systemic lupus erythematosus
Rheumatoid arthritis
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Granulomatosis with polyangiitis.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/granulomatosis-with-polyangiitis/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?